<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03494907</url>
  </required_header>
  <id_info>
    <org_study_id>CR108459</org_study_id>
    <secondary_id>2017-004770-33</secondary_id>
    <secondary_id>42847922MDD1007</secondary_id>
    <nct_id>NCT03494907</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants</brief_title>
  <official_title>A Randomized, Double-blind, Placebo- and Positive-controlled, Single-dose, 4-way Crossover Study to Evaluate the Effects of Seltorexant (JNJ-42847922) on Electrocardiogram Intervals in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of single dose seltorexant on QT/QTc
      intervals and electrocardiogram (ECG) morphology at therapeutic and supratherapeutic
      exposures in healthy adult participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in QT/QTc Intervals</measure>
    <time_frame>Baseline up to Day 3</time_frame>
    <description>Change from baseline in QT and QTc interval will be assessed. QT interval will be measured in triplicates from 12 lead Holter extracted triplicate ECG recordings and corrected QT (QTc) interval will be calculated based on Fridericia (QTcF), Bazett (QTcB), and/or study specific power (QTcP) equations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Change from Baseline in T-wave Morphology</measure>
    <time_frame>Baseline up to Day 3</time_frame>
    <description>The percentage of participants in each treatment having T-wave morphology changes from baseline that represent the appearance or worsening of the morphological abnormality will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Change from Baseline in U-wave Morphology</measure>
    <time_frame>Baseline up to Day 3</time_frame>
    <description>The percentage of participants with change from baseline with abnormal U-waves morphology that represent the appearance or worsening of the morphological abnormality will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose; 0.33, 0.5, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Post-dose</time_frame>
    <description>Cmax is the maximum observed plasma concentration of seltorexant and its circulating metabolites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Pre-dose; 0.33, 0.5, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Post-dose</time_frame>
    <description>Tmax is the time to reach the maximum observed plasma concentration of seltorexant and its circulating metabolites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last])</measure>
    <time_frame>Pre-dose; 0.33, 0.5, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Post-dose</time_frame>
    <description>AUC(0-last) is the area under the plasma concentration-time curve from 0 to time of the last quantifiable concentration of seltorexant and its circulating metabolites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity])</measure>
    <time_frame>Pre-dose; 0.33, 0.5, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Post-dose</time_frame>
    <description>The AUC (0-infinity) is the area under the plasma concentration-time curve from time 0 to infinite time, calculated as the sum of AUC (0-last) and C(last)/lambda(z), in which AUC(0-last) is area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration, C(last) is the last observed quantifiable concentration and lambda(z) is elimination rate constant. AUC (0-infinity) will be assessed for seltorexant and its circulating metabolites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-Life (t1/2)</measure>
    <time_frame>Pre-dose; 0.33, 0.5, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Post-dose</time_frame>
    <description>Elimination half-life associated with the terminal slope Lambda (z) of the semi logarithmic drug concentration-time curve, calculated as 0.693/Lambda (z).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Apparent Clearance (CL/F)</measure>
    <time_frame>Pre-dose; 0.33, 0.5, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Post-dose</time_frame>
    <description>CL/F for extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F)</measure>
    <time_frame>Pre-dose; 0.33, 0.5, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Post-dose</time_frame>
    <description>Vd/F is defined as Dose/[Lambda (z)*AUC (0-infinity)].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite to Parent (M/P) Ratio for AUC[last]</measure>
    <time_frame>Pre-dose; 0.33, 0.5, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Post-dose</time_frame>
    <description>M/P Ratio AUC[last] is the ratio of AUC[last] of seltorexant to AUC[last] of seltorexant's metabolites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite to Parent (M/P) Ratio for AUC[infinity]</measure>
    <time_frame>Pre-dose; 0.33, 0.5, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours Post-dose</time_frame>
    <description>M/P Ratio AUC[infinity] is the ratio of AUC[infinity] of seltorexant to AUC[infinity] of seltorexant's metabolites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between the Plasma Concentrations of Seltorexant and Changes in the QT/QTc Interval</measure>
    <time_frame>Up to Day 3</time_frame>
    <description>The relationship between change in QT/QTc interval and plasma concentrations from both doses of seltorexant at matching time points will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events and Serious Edverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Approximately 11 weeks</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Seltorexant (Low and high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive seltorexant tablets orally in 2 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive moxifloxacin tablets orally in 1 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Matched to Seltorexant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive seltorexant placebo tablets orally in 3 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Matched to Moxifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive moxifloxacin placebo tablets orally in 3 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seltorexant</intervention_name>
    <description>Participants will be administered oral dose of seltorexant over-encapsulated tablets on Day 1.</description>
    <arm_group_label>Seltorexant (Low and high dose)</arm_group_label>
    <other_name>JNJ-42847922</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Matched to Seltorexant</intervention_name>
    <description>Participants will be administered matching placebo to seltorexant tablets on Day 1.</description>
    <arm_group_label>Placebo Matched to Seltorexant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Matched to Moxifloxacin</intervention_name>
    <description>Participants will be administered oral dose of moxifloxacin placebo tablet on Day 1.</description>
    <arm_group_label>Placebo Matched to Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin Dose 1</intervention_name>
    <description>Participants will be administered oral dose 1 of moxifloxacin on Day 1.</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have signed informed consent form (ICF) indicating they understand the purpose of and
             procedures required for the study, including the required pharmacogenomic component
             (which specifies testing of genes predisposing to long or short QT and related cardiac
             syndromes), and are willing to participate in the study. Consent for sample storage
             will be obtained in the ICF

          -  Be Willing to adhere to the prohibitions and restrictions specified in the protocol

          -  A female participant must be either not of childbearing potential (ie, postmenopausal,
             permanently sterile) or of childbearing potential and practicing a highly effective
             method of contraception (failure rate of less than [&lt;]1 percent [%] per year when used
             consistently and correctly)

          -  A female participant must agree not to donate eggs (ova, oocytes) for the purposes of
             assisted reproduction during the study and for at least 1 month after the last study
             drug administration

          -  A male participant, who is sexually active with a woman of childbearing potential and
             has not had a vasectomy, must agree to use an adequate contraception method as deemed
             appropriate by the investigator (eg, vasectomy, double-barrier, partner using
             effective contraception) and to not donate sperm during the study and for 3 months
             after receiving the last dose of study drug

          -  Must have a blood pressure (after the participant is supine for 5 minutes) between 90
             and 140 millimeter of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg
             diastolic. Heart rate between 45 and 100 beats per minute (bpm), inclusive

        Exclusion Criteria:

          -  Clinically significant abnormal values for hematology, serum chemistry (including
             thyroid stimulating hormone [TSH] at screening only) or urinalysis at screening or at
             admission to the study site

          -  Clinically significant abnormal physical examination, vital signs, or 12-lead
             electrocardiogram (ECG) at screening or at admission to the study site as deemed
             appropriate by the investigator

          -  Received a known inhibitor of CYP3A4 or CYP2C9 activity within 14 days or a period
             less than 5 times the drugs' half-life; whichever is longer, before the first dose of
             the study drug is scheduled

          -  Known allergy to the study drug or any of the excipients of the formulation

          -  Received an experimental drug or used an experimental medical device within 1 month or
             within a period less than 10 times the drug's half-life, whichever is longer, before
             the first dose of the study drug is scheduled

          -  A woman who is pregnant, breast-feeding, or planning to become pregnant during the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Pharmacology Unit</name>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108459</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

